Next, we set up a CRC PDX model for drug combination efficacy assays and found that the combination of Cetuximab and Wnt inhibitor (LGK-974) was more efficient in hindering tumor growth than Cetuximab or the LGK-974 inhibitor alone in high CHD6-expressing PDX (case no: 241808) as revealed by the reduced tumor volume, diminished TMEM65 staining, increased cleaved caspase-3 staining, and decreased Ki67 staining (Fig. 8f–h). The gene discussed is TMEM65; the disease is neoplasm.